Loading
A phase 3 trial of Bevacizumab, Carboplatin, Paclitaxel / nab-paclitaxel in non-small-cell lung cancer and small-cell lung cancer, run by Prestige Biopharma Limited, active and no longer recruiting.
A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients is a phase 3 interventional study registered as NCT03390686 by Prestige Biopharma Limited, with 650 participants enrolled, started 2019-11-15 and due to reach its primary completion in 2024-07-01. Interventions recorded: Bevacizumab, HD204, Carboplatin, Paclitaxel. Conditions listed: Lung Cancer, Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.